Bacterial ghosts (BGs)--advanced antigen and drug delivery system (Q37771490)

22 August 2017

1 reference

title

Bacterial ghosts (BGs)--advanced antigen and drug delivery system (English)

1 reference

22 August 2017

1 reference

Pavol Kudela

1

1 reference

22 August 2017

Verena Juliana Koller

series ordinal

2

1 reference

22 August 2017

Werner Lubitz

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

7 July 2010

1 reference

22 August 2017

1 reference

22 August 2017

28

1 reference

22 August 2017

36

1 reference

22 August 2017

5760-5767

1 reference

Recombinant attenuated bacteria for the delivery of subunit vaccines

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Physical properties and in vitro transfection efficiency of gene delivery vectors based on complexes of DNA with synthetic polycations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Use of live bacterial vaccine vectors for antigen delivery: potential and limitations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Potential and limitations of bacterial-mediated cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Cardiovascular toxicity associated with cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Cardiotoxicity induced by chemotherapy and antibody therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Management of metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Bacterial ghosts as carrier and targeting systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Bacterial ghosts--biological particles as delivery systems for antigens, nucleic acids and drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Comparative immunogenicity of the hepatitis B virus core 149 antigen displayed on the inner and outer membrane of bacterial ghosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Effective gene transfer to melanoma cells using bacterial ghosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Bacterial ghosts as novel efficient targeting vehicles for DNA delivery to the human monocyte-derived dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

DNA-loaded bacterial ghosts efficiently mediate reporter gene transfer and expression in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Bacterial ghosts are an efficient delivery system for DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Cell biology of antigen processing in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Activation of lysosomal function during dendritic cell maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

CD4(+) T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Advances in specific immunotherapy of malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Melanoma cell lines are responsive in vitro to lipopolysaccharide and express TLR-4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

TLR4 is the signaling but not the lipopolysaccharide uptake receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Toll-like receptors on tumor cells facilitate evasion of immune surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Toll-like receptor 4 mediates an antitumor host response induced by Salmonella choleraesuis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

DNA vaccines for cancer too.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Minicircle DNA immobilized in bacterial ghosts: in vivo production of safe non-viral DNA delivery vehicles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

Immobilization of plasmid DNA in bacterial ghosts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.087

10.1016/J.VACCINE.2010.06.087

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference